duloxetine hydrochloride + pregabalin + gabapentin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathy, Painful
Conditions
Diabetic Neuropathy, Painful
Trial Timeline
Sep 1, 2006 → Nov 1, 2009
NCT ID
NCT00385671About duloxetine hydrochloride + pregabalin + gabapentin
duloxetine hydrochloride + pregabalin + gabapentin is a approved stage product being developed by Eli Lilly for Diabetic Neuropathy, Painful. The current trial status is completed. This product is registered under clinical trial identifier NCT00385671. Target conditions include Diabetic Neuropathy, Painful.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Neuropathy, Painful were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00385671 | Approved | Completed |
Competing Products
20 competing products in Diabetic Neuropathy, Painful